Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05852990 | Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC | recruiting | Phase 3 | 28 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma(FIERCE-HN) | recruiting | Phase 3 | 410 | AVEO Pharmaceuticals, Inc.INDUSTRY | 18 | Apr 9, 2026 |
| clinicaltrials |
| NCT06810375 | Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery | recruiting | Phase 3 | 120 | George Washington UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06928389 | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer(NSCLC) | recruiting | Phase 3 | 536 | AkesoINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer(VA STARPORT) | recruiting | Phase 2 / Phase 3 | 464 | VA Office of Research and DevelopmentFED | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | recruiting | Phase 3 | 1,800 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06522737 | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype(TERZO) | recruiting | Phase 3 | 124 | SecuraBioINDUSTRY | 10 | Apr 6, 2026 | clinicaltrials |
| NCT06545747 | Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI | recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07481786 | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05226169 | Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) | recruiting | Phase 3 | 330 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06867705 | Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only(RC-102) | recruiting | Phase 3 | 1,458 | ResilienceINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer(Relief) | recruiting | Phase 3 | 121 | Hunan Cancer HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06915727 | An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors | recruiting | Phase 3 | 20 | Mayo ClinicOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC(LUTEON) | recruiting | Phase 3 | 40 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07467083 | Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy | recruiting | Phase 3 | 170 | West China HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | recruiting | Phase 3 | 274 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06954961 | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 640 | InventisBio Co., LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07015892 | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial(ESCALADOR) | recruiting | Phase 3 | 300 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07018869 | Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | recruiting | Phase 3 | 1,057 | SWOG Cancer Research NetworkNETWORK | 3 | Mar 31, 2026 | clinicaltrials |
| NCT07503730 | Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).(EARLY-RIF APL) | recruiting | Phase 3 | 224 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02064673 | Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy | recruiting | Phase 3 | 650 | yair lotanOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 | clinicaltrials |
| NCT06395441 | Wisconsin Ginseng for Decreasing Cancer Related Fatigue | recruiting | Phase 3 | 160 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500701 | Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer | recruiting | Phase 3 | 270 | Samsung Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | recruiting | Phase 3 | 544 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05806060 | Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer(BCTOP-T-M01) | recruiting | Phase 3 | 134 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT06123754 | Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC | recruiting | Phase 3 | 390 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 358 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493109 | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP | recruiting | Phase 3 | 200 | Ou Bai, MD/PHDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07125755 | Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05037279 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)(EVER) | recruiting | Phase 3 | 540 | Verity Pharmaceuticals Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05198960 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms(AVAJAK) | recruiting | Phase 3 | 1,308 | University Hospital, BrestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib(TROPHY-15) | recruiting | Phase 3 | 594 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03594760 | PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer | recruiting | Phase 3 | 1,000 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers(THUNDER) | recruiting | Phase 2 / Phase 3 | 493 | Cancer Research AntwerpOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06497985 | A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | recruiting | Phase 3 | 430 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06563245 | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | recruiting | Phase 2 / Phase 3 | 96 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05738694 | Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma | recruiting | Phase 3 | 298 | ZHOU FANGJIANOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07396480 | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial | recruiting | Phase 3 | 186 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 9, 2026source: clinicaltrials